100 results
F-3
SCNI
Scinai Immunotherapeutics Ltd
30 Jan 24
Shelf registration (foreign)
4:19pm
are a biopharmaceutical company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment … is in the process of developing a pipeline of diversified and commercially viable products built around the licensed innovative nanosized antibodies (NanoAb). NanoAbs
6-K
EX-99.2
SCNI
Scinai Immunotherapeutics Ltd
4 Jan 24
Scinai Immunotherapeutics CEO Issues Letter to Shareholders
4:37pm
focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with an innovative, de-risked
6-K
EX-99.1
SCNI
Scinai Immunotherapeutics Ltd
4 Jan 24
Scinai Immunotherapeutics CEO Issues Letter to Shareholders
4:37pm
to build Scinai into a success by providing caregivers and patients with high quality, innovative, de-risked, pharmaceutical products that help protect … units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with an innovative, de
424B3
SCNI
Scinai Immunotherapeutics Ltd
2 Jan 24
Prospectus supplement
9:58am
products beginning with an innovative, de-risked, pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs
424B3
SCNI
Scinai Immunotherapeutics Ltd
2 Jan 24
Prospectus supplement
9:57am
and immunology (I&I) biological therapeutic products beginning with an innovative, de-risked, pipeline of nanosized VHH antibodies (NanoAbs) targeting
6-K
EX-99.1
nnz0zm1whva042
2 Jan 24
Scinai Immunotherapeutics Announces Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds
9:24am
424B3
medo147pxe8brwuk3
2 Jan 24
Prospectus supplement
8:24am
F-1/A
hucm73i90
22 Dec 23
Registration statement (foreign) (amended)
9:11am
6-K
EX-99.2
ouq3vocj
14 Dec 23
Report of Foreign Private Issuer
6:21am
6-K
axicg 59xbhzft
14 Dec 23
Report of Foreign Private Issuer
6:21am
6-K
EX-99.1
xd7uy5wem7ny0n2 ugf
14 Dec 23
Report of Foreign Private Issuer
6:21am
6-K
EX-99.1
e42b9jy3
20 Nov 23
Report of Foreign Private Issuer
10:49am
6-K
btxk9mo
13 Nov 23
Report of Foreign Private Issuer
8:25am
6-K
EX-99.1
5361je 1dd
7 Nov 23
Scinai Immunotherapeutics Announces Award of Non-Dilutive Grant from Israel Innovation Authority Supporting its New CDMO Business Unit
6:09am
6-K
EX-99.1
igjf4jk4ja2
3 Nov 23
Report of Foreign Private Issuer
8:49am
6-K
EX-99.1
vp46 j9zg8zklsjl
2 Nov 23
Scinai Reports Third Quarter 2023 Financial Results and Provides Business Update
1:21pm
F-1
7gds7yl3rr kgm2ql1
30 Oct 23
Registration statement (foreign)
4:59pm
6-K
EX-99.1
btws irff9lh
20 Sep 23
Scinai Immunotherapeutics Announces Closing of $1.33 Million Registered Direct Offering
6:08am
6-K
EX-1.5
7nj8 3641hgjpjbk4q
19 Sep 23
Report of Foreign Private Issuer
3:06pm
424B5
fcxaj3rsk
19 Sep 23
Prospectus supplement for primary offering
10:03am